• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

作者信息

Tonkin Andrew M, Chen Lei

机构信息

Cardiovascular Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, 99 Commercial Rd, Melbourne, Victoria 3004, Australia.

出版信息

Circulation. 2010 Aug 24;122(8):850-2. doi: 10.1161/CIRCULATIONAHA.110.960112.

DOI:10.1161/CIRCULATIONAHA.110.960112
PMID:20733114
Abstract
摘要

相似文献

1
Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.糖尿病控制心血管风险行动（ACCORD）试验中联合降脂治疗对2型糖尿病患者的管理效果。
Circulation. 2010 Aug 24;122(8):850-2. doi: 10.1161/CIRCULATIONAHA.110.960112.
2
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).辛伐他汀单药、非诺贝特单药以及辛伐他汀联合非诺贝特对混合性血脂异常糖尿病患者脂蛋白亚组分谱的影响比较（来自糖尿病与联合脂质治疗方案研究）
Am J Cardiol. 2008 Feb 15;101(4):486-9. doi: 10.1016/j.amjcard.2007.09.095. Epub 2007 Dec 26.
3
[Dyslipidemia in diabetes mellitus].[糖尿病中的血脂异常]
Ned Tijdschr Geneeskd. 2001 Apr 21;145(16):769-74.
4
Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.糖尿病心血管风险控制行动（ACCORD）试验中强化血压控制对2型糖尿病患者管理的影响。
Circulation. 2010 Aug 24;122(8):847-9. doi: 10.1161/CIRCULATIONAHA.110.960120.
5
[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].糖尿病血脂异常的治疗在糖尿病血脂控制心血管风险行动研究后是否应进行调整？
Endocrinol Nutr. 2010 Dec;57(10):457-9. doi: 10.1016/j.endonu.2010.05.010. Epub 2010 Aug 4.
6
Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.辛伐他汀对2型糖尿病患者的降脂作用。
Indian Heart J. 2001 Mar-Apr;53(2):172-6.
7
Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.氟伐他汀与非诺贝特联合治疗与氟伐他汀单药治疗在合并高脂血症、2型糖尿病和冠心病中的疗效比较：一项为期12个月的随机双盲对照试验。
Clin Ther. 2004 Oct;26(10):1599-607. doi: 10.1016/j.clinthera.2004.10.008.
8
Clinical trials and lipid guidelines for type II diabetes.2型糖尿病的临床试验与血脂指南
J Clin Pharmacol. 2004 Apr;44(4):423-30. doi: 10.1177/0091270004263016.
9
ACCORD and Risk-Factor Control in Type 2 Diabetes.2型糖尿病中的ACCORD研究与危险因素控制
N Engl J Med. 2010 Apr 29;362(17):1628-30. doi: 10.1056/NEJMe1002498. Epub 2010 Mar 14.
10
ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients.
Cardiovasc J Afr. 2010 Mar-Apr;21(2):118-9.

引用本文的文献

1
Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.载脂蛋白C3与降低低密度脂蛋白胆固醇的变异体对冠心病风险的联合影响
JAMA Cardiol. 2025 May 1;10(5):463-472. doi: 10.1001/jamacardio.2025.0195.
2
Lipid-lowering effects of gefarnate in statin-treated patients with residual hypertriglyceridemia: a randomized controlled study.吉非贝齐对他汀类药物治疗后仍存在高甘油三酯血症患者的降脂作用：一项随机对照研究。
J Geriatr Cardiol. 2024 Aug 28;21(8):791-798. doi: 10.26599/1671-5411.2024.08.001.
3
The metabolic vascular syndrome - guide to an individualized treatment.
代谢性血管综合征——个体化治疗指南
Rev Endocr Metab Disord. 2016 Mar;17(1):5-17. doi: 10.1007/s11154-016-9345-4.
4
Critical appraisal of international guidelines for the management of diabetic neuropathy: is there global agreement in the internet era?糖尿病神经病变管理国际指南的批判性评价：在互联网时代是否存在全球共识？
Int J Endocrinol. 2015;2015:519032. doi: 10.1155/2015/519032. Epub 2015 Apr 27.
5
Therapeutic approaches to diabetic nephropathy--beyond the RAS.治疗糖尿病肾病的方法——超越 RAS。
Nat Rev Nephrol. 2014 Jun;10(6):325-46. doi: 10.1038/nrneph.2014.74. Epub 2014 May 6.
6
Origin and therapy for hypertriglyceridaemia in type 2 diabetes.2型糖尿病中高甘油三酯血症的起源与治疗
World J Diabetes. 2014 Apr 15;5(2):165-75. doi: 10.4239/wjd.v5.i2.165.
7
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.残余心血管风险的分子来源、临床信号及创新解决方案：与亚临床疾病、治疗不足及依从性差的关系：新证据对优化心血管疾病患者预后的影响
Vasc Health Risk Manag. 2013;9:617-70. doi: 10.2147/VHRM.S37119. Epub 2013 Oct 21.
8
Fenofibrate: a review of its use in dyslipidaemia.非诺贝特：用于血脂异常的综述。
Drugs. 2011 Oct 1;71(14):1917-46. doi: 10.2165/11208090-000000000-00000.